Klinik und Poliklinik für Neurologie


Wüllner U, Kupsch A, Renner P, Arnold G, Scheid C, Scheid R, Oertel W, Klockgether T (1992): The competitive NMDA-antagonist CGP40116 enhances L-DOPA response in MPTP treated marmosets. Neuropharmacology 31, 713-715 IF 3.8

Hantraye P, Brownell A-L, Elmaleh D, Spealman RD, Wüllner U, Brownell GL, Madras BK, Isacson O (1992): Dopaminergic fiber detection by 11C-CFT and PET in a primate model of Parkinson's disease. Neuroreport 3, 265-268 IF 2.5

Wüllner U, Brouillet E, Isacson O, Penney JB, Young AB (1993): Glutamate receptor binding sites in MPTP-treated mice. Experimental Neurology 121, 284-287 IF 3.7

Burns L, Sato M, Wüllner U, Isacson O (1993): Intra-nigral infusion of AMPA attenuates dopamine dependent rotation in the rat. Neuroreport 4, 1075-1078 IF 2.5

Brownell A-L, Hantraye P, Wüllner U, Hamberg L, Shoup T, Elmaleh D, Frim DM, Madras BK, Brownell GL, Rosen BR, Isacson O (1993): PET and MRI based assessment of glucose utilization, dopamine receptor density and haemodynamic changes after lesions to the caudate-putamen in primates. Experimental Neurology 125, 41-51 IF 3.7

Wüllner U, Standaert DG, Testa CM, Landwehrmeyer GB, Catania MV, Penney JB and Young AB (1994): Glutamate receptor expression in rat striatum: effect of deafferentation. Brain Research 647, 209-219 IF 2.5

Wüllner U, Testa CM, Catania MV, Penney JB and Young AB (1994): Glutamate receptors in striatum and substantia nigra: effects of medial forebrain bundle lesions. Brain Research 645, 98-102 IF 2.5

Wüllner U, Hantraye P, Brownell A-L, Pakzaban P, Burns L, Shoup T, Elmaleh D, Petto AJ, Spealman RD, Brownell GL, Isacson O (1994): Dopamine terminal loss and onset of motor symptoms in MPTP treated monkeys - a positron emission tomography study with 11C-CFT. Experimental Neurology 126, 305-309 IF 3.7

Löschmann P-A, Eblen F, Wüllner U Wachtel H, Klockgether T (1995): Lamotrigene has no antiparkinsonian activity in rat models of Parkinson's disease. European Journal of Pharmacology 284, 129-134 IF 2.4

Löschmann P-A, Eblen F, Wüllner U, Klockgether T (1995): NMDA-mediated toxicity to striatal neurons is not reversed by 7-nitroindazole an inhibitor of neuronal nitric oxide synthase. Journal of Neural Transmission Suppl 46, 87-95 IF 2.5

Eblen F, Löschmann P-A, Wüllner U, Turski L, Klockgether T, (1996): Effects of 7-nitroindazole NG-nitro-L-arginine and D-CPPene on harmaline-induced postural tremor N-methyl-D-aspartate-induced seizures and lisuride-induced rotations in rats with nigral 6-hydroxydopamine lesions. European Journal of Pharmacology 299, 9-16 IF 2.4

Wüllner U, Löschmann P-A, Schmid A, Dringen R, Eblen F, Turski L Klockgether T (1996): Glutathione depletion potentiates MPTP and MPP+ toxicity in nigral dopaminergic neurons. Neuroreport 7, 921-923 IF 2.5

Klockgether T, Wüllner U, Steinbach JP, Petersen V, Turski L, Löschmann P-A (1996): Effects of the antiparkinsonian drug budipine on cerebral neurotransmitter systems. European Journal of Pharmacology 301, 67-73 IF 2.4

Weller M, Schulz JB, Wüllner U, Löschmann P-A, Klockgether T, Dichgans J (1997): Developmental and genetic regulation of programmed neuronal death. Journal of Neural Transmission Suppl 50, 115-123 IF 2.5

Wüllner U, Standaert DG, Testa CM, Penney JB, Young AB (1997): Differential expression of kainate receptors in the basal ganglia of the developing and adult rat brain. Brain Research 768, 215-223 IF 2.5

Löschmann P-A, Wüllner U, Heneka M, Schulz JB, Kunow M, Wachtel H, Klockgether T (1997): Differential interaction of competitive NMDA and AMPA antagonists with selective dopamine D-1 and D-2 agonists in a rat model of Parkinson's disease. Synapse 26, 381-391 IF 2.9

Wüllner U, Weller M, Groscurth P, Löschmann P-A, Schulz JB, Müller I, Klockgether T, (1997): Evidence for an active type of cell death with ultrastructural features distinct from apoptosis: the effects of 3-acetylpyridine neurotoxicity. Neuroscience 81, 721-734 IF 3.6

Wüllner U, Kornhuber J, Weller M Schulz JB, Riederer P, Klockgether T (1999): Apoptosis in Parkinson's disease: a cautionary note. Acta Neuropathologica 97, 408-412 IF 2.6

de Groote C, Wüllner U, Löschmann P-A, Luiten PGM, Klockgether T (1999): Functional characterization and expression of GABAB receptors in a rodent model of Parkinson's disease. Neuropharmacology 38, 1683-1689 IF 3.8

Evert BO, Wüllner U, Schulz JB, Weller M, Groscurth P, Trottier Y, Brice A, Klockgether T (1999): High level expression of expanded full-length ataxin-3 in vitro causes cell death and formation of intranuclear inclusions in neuronal cells. Human Molecular Genetics 8, 1169-1176 IF 8.6

Heneka MT, Feinstein DL, Galea E, Gleichmann M, Wüllner U, Klockgether T,(1999): Peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonists protect cerebellar granule cells from cytokine-induced apoptotic cell death by inhibition of inducible nitric oxide synthase. Journal of Neuroimmunology 100, 156-168 IF 3.0

Seyfried J, Soldner F, Schulz JB, Kovar KA, Klockgether T, Wüllner U (2000): Effect of 1-methyl-4-phenylpyridinium on glutathione homoeostasis in PC 12 cells. Neurochemistry International 36, 489-497 IF 3.3

Wüllner U, Weller M, Kornhuber J, Bornemann A, Schulz JB, Riederer P, Klockgether T (2000): Calcium Binding And Apoptosis Modulating Proteins In Multiple System Atrophy. Movement Disorders 15, 269-275 IF 3.1

Paus S, Brecht HM, Köster J, Seeger G, Klockgether T, Wüllner U (2003): Sleep attacks daytime sleepiness and dopamine agonists in Parkinson's disease. Movement Disorders 18, 659-67 IF 3.1

Paus S, Brecht HM, Klockgether T, Wüllner U (2003): Sleep attacks may not be a side effect of dopaminergic medication. Movement Disorders 18, 1571 IF 3.1

Specht K, Minnerop M, Abele M, Reul J, Wüllner U, Klockgether T (2003): In vivo voxel-based morphometry in multiple system atrophy of cerebellar type (MSA-C). Archives of Neurology 60, 1413-1435 IF 4.7

Abele M, Riet A, Hummel T, Klockgether T, Wüllner U (2003): Olfactory dysfunction in cerebellar ataxia and multiple system atrophy. Journal of Neurology 250, 1453-1455 IF 2.8

Wüllner U, Abele M, Schmitz-Hübsch T, Wilhelm K, Deuschl G, Beneke R, Klockgether T (2004): Multiple System Atrophy in a German family. Journal of Neurology, Neurosurgery and Psychiatry, 75, 924-925 IF 3.0

Schmaljohann J, Minnerop M, Karwath P, Gündisch D, Falkai P, Guhlke S, Wüllner U (2004): Imaging of central nAChReceptors with 2-[18F]F-A85380: optimized synthesis and in vitro evaluation in Alzheimer's disease. Applied Radiation and Isotopes, 61, 1235-1240 IF 0.7

Paus S, Seeger G, Brecht HM, Köster J, El-Faddagh M, Nöthen M, Klockgether T, Wüllner U (2004): Association study of dopamine D2, D3, D4 receptor and serotonin transporter gene polymorphisms with sleep attacks in Parkinson's disease. Movement Disorders, 6, 705-707 IF 3.1

Möller JC, Depboylu C, Kölsch H, Lohmüller F, Bandmann O, Gocke P, Dud Y, Paus S, Wüllner U, Gasser T, Oertel WH, Klockgether T, Dodel RC (2004): Lack of Association between the Interleukin-1 alpha (-889) Polymorphism and Early-Onset Parkinson's Disease Neuroscience Letters, 359, 195-197. IF 2.0

Löschmann P-A, de Groote C, Smith L, Wüllner U, Fischer G, Kemp JA, Jenner P, Klockgether T (2004): Antiparkinsonian activity of Ro 25-6981 a NR2B subunit specific NMDA receptor antagonist in animal models of Parkinson´s disease. Experimental Neurology 187, 86-93 IF 3.8

Abele M, Klockgether T, Wüllner U (2004): Spectral analysis of heart rate variability in Multiple System Atrophy and Parkinson's disease. Journal of Neurology, 251, 894-905 IF 2.8

Healy DG, Abou-Sleiman PM, Ozawa T, Lees AJ, Bhatia K, Ahmadi KR, Wüllner U, Berciano J, Möller JC, Kamm C, Bürk K, Pellecchia MT, Tolosa E, Quinn N, Goldstein DB, Wood NW (2004): Functional polymorphism regulating dopamine beta hydroxylase plasma activity protects against Parkinson¹s disease. Annals of Neurology 55, 443-446. IF 7.7

Linnebank M, Linnebank A, Jeub M, Klockgether T, Wüllner U, Kölsch H, Heun R, Koch HG, Suormala T, Fowler B (2004). Lack of Genetic Dispositions to Hyperhomocysteinemia in Alzheimer's disease. American Journal of Medical Genetics, 131, 101-102 IF 2.6

Buervenich S, Carmine A, Galter D, Shahabi N, Johnels B, Holmberg B, Ahlberg J, Nissbrandt H, Eerola J, Hellström O, Pentti JT, Matsuura T, Ashizawa T, Wüllner U, Klockgether T, Zimprich A, Gasser T, Hanson M, Singleton A, McMahon F, Anvret M, Sydow O, Olson L (2005): A Rare Truncating Mutation in ADH1C (G78stop) Shows Significant Association with Parkinson's Disease in a Large International Sample. Archives of Neurology, 62, 74-78 im 4.7

Minnerop M, Kornblum C, Joe AY, Tatsch K, Kunz W, Klockgether T, Wüllner U, Reinhardt MJ (2005): Dopamine transporter SPECT in patients with mitochondrial disorders. Journal of Neurology, Neurosurgery and Psychiatry, 76, 118-120 IF 3.0

Kölsch H, Linnebank M, Lütjohann D, Jessen F, Wüllner U, Harbrecht U, Thelen KM, Kreis M, Hentschel F, Schulz A, von Bergmann K, Maier W, Heun D. Polymorphisms in glutathione S-transferase omega-1 and AD, vascular dementia, and stroke. Neurology 2004;63:2255-2260

Mueller JC, Fuchs J, Hofer A, Zimprich A, Lichtner P, Illig T, Berg D, Wüllner U, Meitinger T, Gasser T. Multiple regions of alpha-synuclein are associated with Parkinson's disease. Annals of Neurology 2005;57:535-41. IF 7.7

Berg D, Niwar M, Maass S, Zimprich A, Moeller C, Wüllner U, Klein C, Tan E, Schoels L, Marsh L, Dawson T, Janetzky B, Müller T, Woitalla D, Dufke A, Bauer P, Krueger R, Gasser T, Riess O. Alpha-synuclein and Parkinson_s disease - implications from the screening of more than 1900 patients. Movement Disorders, 2005;20:1191-4 IF 3.1

Kamm C, Healy DG, Quinn NP, Wüllner U, Moeller JC, Schoels L, Geser F, Buerk K, Boerglum A, Pellecchia MT, Tolosa E, del Sorbo F, Nilsson C, Bandmann O, Sharma M, Mayer P, Gasteiger M, Haworth A, Ozawa T, Lees AJ, Holinski-Feder E, Illig T, Wichmann E, Wenning GK, Wood NW, Gasser T for the European Multiple System Atrophy (EMSA) Study Group, The Fragile X Tremor Ataxia Syndrome in the differential diagnosis of MSA: data from the EMSA study group. Brain, 2005;128:1855-60 IF 8.0

Schmitz-Hubsch T, Pyfer D, Kielwein K, Fimmers R, Klockgether T, Wüllner U: Qigong exercise for the symptoms of Parkinson's disease: a randomized, controlled pilot study. Movement Disorders, 2005;21:543-548 IF 3.1

Healy DG, Abou-Sleiman PA, Quinn N, Ahmadi KR, Ozawa T, Kamm C, Wüllner U, Oertel WH, Bürk K, Dupont E, Pellecchia MT, Tolosa E, Gasser T, Holton JL, Revesz T, Goldstein DB, Lees AJ, Wood NW and the European MSA study group. The UCHL-1 gene in MSA - a haplotype tagging approach. Movement disorders, 2005;20:1338-43. IF 3.1

Breit S, Reimold M, Reischl G, Klockgether T, Wüllner U. 11C-methylphenidate PET in Patients with Parkinson's disease and Essential Tremor. Journal of Neural Transmission, 2006;113:187-93 IF 2.5

Linnebank M, Fliessbach K, Kölsch H, Rietschel M, Wüllner U. The methionine synthase polymorphism c.2756A>G (D919G) is associated with disease-free longevity. Int J Mol Med 2005;16:759-61 IF 1.9

Minnerop M, Lutz M, Bauer P, Joe A, Reinhardt M, Wüllner U. Dopamine transporter and cerebral glucose metabolism in SCA 17. Annals of Neurology, 2005;58:490-491 IF 7.7

Biskup S, Mueller J, Lichtner P, Zimprich A, Sharma M, Illig T, Wüllner U, Gasser T, Meitinger T. Common variants of LRRK2 are not associated with sporadic Parkinson disease Annals of Neurology, 2005;58:905-908 IF 7.7

Wüllner U, Kölsch H, Linnebank M. 1. Methylenetetrahydrofolate reductase in Parkinson's disease. Annals of Neurology, 2005;58:972-973 IF 7.7

Ozawa T, Healy DG, Abou-Sleiman, PM, Ahmadi KR, Quinn N, Lees AJ, Shaw K, Wüllner U, Berciano J, MollerJC, Kamm C, Burk K, Josephs KA, Barone P, Tolosa E, Goldstein DB, Wenning G, Geser F, Holton JL, Gasser T, Revesz T, Wood, NW, the European MSA study group. The alpha synuclein gene in multiple system atrophy. Journal of Neurology, Neurosurgery and Psychiatry, 2006;77:464-467 IF 3.0

Schmaljohann J, Gundisch D, Minnerop M, Bucerius J, Alexis J, Reinhardt M, Guhlke S, Biersack H-J, Wüllner U. In vitro evaluation of nicotinic acetylcholine receptors with 2-[18F]F-A85380 in Parkinson's disease. Nuclear Medicine and Biology, 2006;33(3):305-9 IF 1.7

Vogt IR, Lees AJ, Klockgether T, Bonin M, Evert BO, Wüllner U. Expression profiling of specific brain regions in Multiple system Atrophy and Parkinson's disease. Exp Neurol, 2006;199(2):465-78 IF 3.5

Schmitt I, Wüllner U, Healy DG, Wood NW, Kolsch H, Heun R. The ADH1C stop mutation in multiple system atrophy patients and healthy probands in the United Kingdom and Germany. Mov Disorders 2006;21:2034 IF 3.1

Eggert K, Wüllner U, Antony G, Gasser T, Janetzky B, Klein C, Schöls L, Oertel WH. Data protection in biomaterial banks for Parkinson's disease research: The model of GEPARD (Gene Bank Parkinson's Disease Germany). Mov Disorders, 2007;22(5):611-618. IF 3.1

Minnerop M, Specht K, Ruhlmann J, Schimke N, Abele M, Weyer A, Wüllner U, Klockgether T. Voxel-based morphometry and voxel-based relaxometry in multiple system atrophy - A comparison between clinical subtypes and correlations with clinical parameters. Neuroimage, 2007;36(4):1086-95

Wüllner U, Schmitz-Hübsch T, Abele M, Antony G, Bauer P, Eggert K. Features of probable Multiple System Atrophy patients identified among 4770 patients with parkinsonism enrolled in the multicentre registry of the German Competence Network on Parkinson's disease Journal of Neural Transmission, 2007;114(9):1161-5.

Paus S, Schmitz-Hübsch T, Wüllner U, Vogel A, Klockgether T, Abele M. Bright light therapy in Parkinson's Disease: A Pilot Study. Movement Disorders, 2007;22(10):1495-8

Wüllner U, Schmitz-Hübsch T, Antony G, Fimmers R, Spottke A, Oertel WH, Deuschl G, Eggert K. Autonomic dysfunction in 3414 Parkinson's disease patients enrolled in the German Network on Parkinson's disease (KNP e.V.). European Journal of Neurology, 2008; 14(12):1405-8.

Popp J, Schaper K, Kölsch H, Cvetanovska G, Rommel F, Klingmüller D, Dodel R, Wüllner U, Jessen F. CSF Cortisol in Alzheimer's Disease and Mild Cognitive Impairment. Neurobiology of Aging, in press

Fuchs J, Mueller JC, Lichtner P, Schulte C, Munz M, Berg D, Wüllner U, Illig, T, Sharma M, Gasser T. The transcription factor PITX3 is associated with sporadic Parkinson's disease: Neurobiology of Aging, in press

Paus S, Grünewald A, Klein C, Knapp M, Zimprich A, Janetzky B, Möller JC, Klockgether T, Wüllner U. The DRD2 TaqIA polymorphism and demand of dopaminergic medication in Parkinson's disease. Movement Disorders, 2008;23(4):599-602.

Mueller MC, Jueptner U, Wüllner U, Wirz S, Tuerler A, Wirtz DC, Hirner A, Standop, J. Parkinson's disease influences the perioperative risk profile in traumapatients. Zeitschrift für Orthopädie und Unfallchirurgie, 2008, 146(2):227-30

Standop J, Jüptner U, Müller M, Overhaus M, Wirz S, Hirner A, Wüllner U. Postoperative Komplikationen bei Patienten mit Parkinson'scher Krankheit - Medizinische und ökonomische Aspekte. Aktuelle Neurologie, 2008, 6, 285-289

Pieper H, Evert BO, Kaut O, Riederer P, Waha A, Wüllner U. Different methylation of the TNF-alpha promoter in cortex and substantia nigra: implications for selective neuronal vulnerability. Neurobiology of Disease, 2008, 32(3):521-7

Rakovic A, Stiller B, Djarmati A, Flaquer A, Freudenberg J, Toliat MR, Linnebank M, Kostic V, Lohmann K, Paus S, Nürnberg P, Kubisch C, Klein C, Wüllner U, Ramirez A. Genetic association study of the P-type ATPase ATP13A2 in late onset Parkinson disease. Movement Disorders, 2009, 24(3):429-33

Mueller MC, Jüptner U, Wuellner U, Wirz S, Türler A, Hirner A, Standop J. Parkinson's disease influences the perioperative risk profile in surgery. Langenbecks Arch Surg. 2008, 146(2):227-30

Wüllner U, Schmitt I, Kammala M, Kretzschmar HA, Neumann M. Definite Multiple System Atrophy in a German Family. JNNP, 2009, 80(4):449-50

Paus S, Gadow F, Knapp M, Klein C, Klockgether T, Wüllner U. Motor complications in patients form the German Competence Network on Parkinson's disease and the DRD3 Ser9Gly polymorphism. Movement Disorders, 2009, 24(7):1080-4

Scholz SW, Houlden H; Schulte C, Sharma M, Li A, Berg D, Melchers A, Segarane B, Gibbs JR, Simon-Sanchez J, Paisan-Ruiz C, Bras J, Ding J, Chen H, Traynor BJ, Arepalli S, Zonozi RR; Revesz T, Holton J, Oertel WH, Wüllner U, Goldwurm S, Pellecchia M, Illig T, Riess O, Fernandez HH, Rodriguez RL, Okun MS, Poewe W, Wenning GK, Hardy JA, Singleton AB; Gasser T. SNCA variants are associated with increased risk of multiple system atrophy. Ann Neurol, 2009, 65(5):610-4

Schmitz-Hübsch T, Frommann I, Hoenig K, Minnerop M, Wüllner U, Wagner M. Reinforcement learning and executive functioning in Multiple System Atrophy - dissociation between clinical phenotypes of cerebellar and parkinsonian predominance. Movement Disorders, in press

Müller T, Breuer P, Schmitt I, Evert BO, Wüllner U. CK2 Dependent Phosphorylation Determines Cellular Localization and Stability of Ataxin-3. Human Molecular Genetics, 2009, 18(17):3334-43

Bauer P, Stevanin G, Synofzik M, Schmitz-Hübsch T, Wüllner U, Riess O, et al. Spinocerebellar ataxia type 11 (SCA11) is a rare cause of dominant ataxia in European patients. JNNP, 2010, in press

Breuer P, Haake N, Evert BO, Wüllner U. Nuclear aggregation of polyglutamine-expanded ataxin 3: Fragments escape the cytoplasmic the cytoplasmic quality control (JBC/2009/036335). JBC, 2010, in press

Paus S Tremor in Parkinson's disease is not associated to the DRD3 Ser9Gly polymorphism. Parkinsonism & Related Disorders, in press

Wüllner U, et al. Transdermal rotigotine for the perioperative management of Parkinson's disease. JNT, 2010, in press

Jowead A, Schmitt I, Kaut O, Wüllner U. Methylation of alpha-synuclein regulates expression and is decreased in Parkinson's disease patient's brains. JNeurosci, 2010, in press

Synofzik M, Beetz C, Bauer C, Bonin M, Schmitz-Hübsch T, Wüllner U, Nägele T, Riess O, Schöls L, Bauer P. Frequency, phenotypic spectrum and disease progression in SCA 15. revision Brain

Gispert S, Kurz A, Double KL, Lastres-Becker I, Tozzi A, Tantucci M, Bockhart V, Bonin M, Fernandez-Ruiz J, Gerlach M, Wüllner U, Lueddens H, Calabresi P, Auburger G. A53T-alpha-Synuclein Overexpression Impairs Dopamine Signaling and Striatal Synaptic Plasticity in Old Mice. revision PLOS

Mueller MC, Wüllner U, Hirner A, Wirz S, Standop J. Inadäquate DRG-Vergütung chirurgischer Patienten mit Morbus Parkinson. Zentralblatt für Chirurgie - Zeitschrift für Allgemeine, Vizeral- und Gefäßchirurgie, in press

Minnerop M, Wüllner U. Callosal tissue loss in multiple system atrophy - a one year follow-up MRI-study. Movement Disorders, revision

Klinke I, Minnerop M, Schmitz-Hübsch T, Hendriks M, Klockgether T, Wüllner U, Helmstaedter C. Neuropsychological Features of Patients with Spinocerebellar Ataxia (SCA) Type 1, 2, 3 and 6. Movement Disorders, in press